Research that Makes a Difference in the Lives of Cancer Patients
Genprex is focused on providing new solutions to solveLearn More
today’s problems in fighting cancer.
Striving to Provide a Healthier Tomorrow for Cancer Patients
Genprex is dedicated to improving patients’ lives by increasing the treatment potential of currently marketed and developmental cancer drugs.Learn More
Focused on Building Strong, Long-term Relationships
Genprex is forming commercial partnerships for worldwide development and marketing of our products and technology applications.Learn More
Genprex is a privately held, clinical-stage biopharmaceutical company developing nanovesicle therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. The company’s pan-kinase inhibitors work to induce apoptosis (programmed cell death) in cancer cells and to control cell signaling and inflammatory pathways. These biologic therapies target key oncogenic pathways to treat tumors and cancer metastases at the molecular level without harming normal cells. Used in combination with other targeted therapies, these drugs overcome genomic limitations inherent with targeted therapies including tyrosine kinase inhibitory drugs (TKIs). Genprex technologies also can be used to reduce drug resistance in patients with intrinsic or acquired drug resistance. Our products will broadly participate in the global oncology marketplace by addressing the unmet medical needs of cancer patients and expanding populations of patients benefiting from our combination treatments.